234 Church Street
About Biohaven Pharma
100 articles with Biohaven Pharma
Biohaven Advances NOJECTION™ Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological and neuropsychiatric diseases, today announced completion of enrollment in its Phase 2/3, double-blind, randomized, placebo-controlled, dose-ranging trial of intranasally administered vazegepant (formerly BHV-3500) for the acute treatment of migraine
Rimegepant is the only oral CGRP receptor antagonist currently in development for both the acute and preventive treatment of migraine
Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled
Biohaven Pharmaceutical Holding Company Ltd. announced that enrollment in the T2 Protect AD Study, a Phase 2/3 clinical trial of troriluzole in Alzheimer's disease, is progressing on timelines with more than 400 subjects enrolled and over 180 subjects randomized to study treatment.
7/22/2019Here's a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more.
Biohaven's Nurtec 505(b)2 Application for Amyotrophic Lateral Sclerosis Affected by Issues Related to Apotex Plant: Complete Response Letter (CRL) Received From FDA Related to Isolated Drug Substance Supply Used in Bioequivalence Study
Biohaven Pharmaceutical Holding Company Ltd. announced that it has received a Complete Response Letter from the FDA for the 5052 application seeking approval for NURTEC™ for ALS.
7/15/2019It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.
Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety
Rimegepant Zydis® Oral Fast-Dissolve Tablet (ODT) Phase 3 results demonstrate rapid and sustained benefits for the acute treatment of migraine
Biohaven Launches 'Demand More' Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Needs In Acute Treatment Of Migraine
Research suggests patients define effective migraine therapies as reliable pain relief that enables them to return to their lives. Current treatments limit the ability for some patients to reach their treatment goals due to nonresponse to standard therapies and side effects.
Biohaven To Present 16 Abstracts At 2019 American Headache Society (AHS) Annual Scientific Meeting Highlighting New Data With Rimegepant, Oral CGRP Receptor Antagonist
Rimegepant leads the meeting with the most presentations for an oral small molecule CGRP receptor antagonist, including 14 late breakers
Biohaven has granted the underwriters a 30-day option to purchase up to an additional 1,046,511 common shares at the public offering price, less underwriting discounts and commissions
Biohaven Pharmaceutical Holding Company Ltd. announced that it has commenced an underwritten public offering of $300 million of its common shares.
Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-Term Safety Study, And Presents Case Reports Of Using Rimegepant To Successfully Treat Breakthrough Migraine Attacks In Patients Taking Preventive CGRP
Over 105,000 doses of rimegepant 75 mg have been administered in over 1,780 migraine patients in the long-term safety study to date
Phase 2/3 clinical trials of troriluzole, a glutamate modulator, in Alzheimer's disease, generalized anxiety disorder, and obsessive-compulsive disorder are all expected to complete enrollment by end of 2019
Biohaven Pharmaceuticals Reports First Quarter 2019 Financial Results And Advancements In Neuroinnovation Platforms
Secured Priority Review Voucher (PRV) enabling expedited regulatory review of rimegepant Zydis® ODT New Drug Application (NDA)
William "BJ" Jones joins Biohaven as Chief Commercial Officer, Migraine and Common Diseases
Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute Treatment of Migraine
BHV-3500 is the first CGRP receptor antagonist drug candidate to be administered in an intranasal (IN) formulation in late stage testing and is Biohaven's second drug candidate from its NOJECTION™ migraine platform
Biohaven Secures Priority Review Voucher (PRV) To Expedite Regulatory Review Of Rimegepant Zydis ODT New Drug Application
Rimegepant Zydis orally disintegrating tablet (ODT) is Biohaven's lead oral CGRP receptor antagonist drug candidate from its NOJECTION™ migraine platform
Company Announces Expanded Data From Troriluzole Phase IIb/III Long-Term Extension Study Compared To Matched Natural History Cohort
Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant
-Biohaven remains on-track for new drug application (NDA) submission for rimegepant Zydis ODT and tablet formulation in 2Q2019
Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial And Recent Business Results
Positioned to submit New Drug Applications (NDA) for rimegepant Zydis ODT and tablet formulations for the acute treatment of migraine in 2Q2019